Literature DB >> 32170563

Clinical outcomes of tumor bleeding in duodenal gastrointestinal stromal tumors: a 20-year single-center experience.

Gyu Young Pih1, Ji Yong Ahn2, Ji Young Choi3, Hee Kyong Na1, Jeong Hoon Lee1, Kee Wook Jung1, Do Hoon Kim1, Kee Don Choi1, Ho June Song1, Gin Hyug Lee1, Hwoon-Yong Jung1.   

Abstract

BACKGROUND: Duodenal gastrointestinal stromal tumors (GISTs) are rare, and reports on duodenal GIST bleeding are few. We analyzed the risk factors and clinical outcomes of hemorrhagic duodenal GISTs and compared them with those of gastric GISTs.
METHODS: Primary duodenal GISTs surgically diagnosed between January 1998 and December 2017 were retrospectively reviewed. Furthermore, patients with duodenal GIST were compared with those with primary gastric GIST histopathologically diagnosed between January 1998 and May 2015 using previously published data.
RESULTS: Of the 170 total patients with duodenal GISTs, 48 (28.2%) exhibited tumor bleeding. Endoscopic intervention, embolization, and non-interventional conservative treatment were performed for initial hemostasis in 17, 1, and 30 patients, respectively. The 5-year survival rate was 81.9% in the bleeding group and 89.4% in the non-bleeding group (P = 0.495). Multivariate analysis showed that p53 positivity was a significant risk factor for duodenal GIST bleeding (hazard ratio [HR] 2.781, P = 0.012), and age ≥ 60 years (HR 3.163, P = 0.027), a large maximum diameter (comparing four groups: < 2, 2-5, 5-10, and ≥ 10 cm), and mitotic count ≥ 5/high-power field (HPF) (HR 3.265, P = 0.032) were risk factors for overall survival. The incidence of bleeding was significantly higher in duodenal GISTs than in gastric GISTs (28.2% vs. 6.6%, P < 0.001), and the re-bleeding rate after endoscopic hemostasis was also higher in duodenal GISTs than in gastric GISTs (41.2% vs. 13.3%, P = 0.118).
CONCLUSION: In patients with duodenal GIST with old age, large tumor diameter, and mitotic count ≥ 5/HPF, a treatment plan should be established in consideration of the poor prognosis, although tumor bleeding does not adversely affect the prognosis. Duodenal GISTs have a higher incidence of tumor bleeding and re-bleeding rate after endoscopic hemostasis than gastric GISTs.

Entities:  

Keywords:  Duodenum; Endoscopy; Gastrointestinal stromal tumor

Mesh:

Year:  2020        PMID: 32170563     DOI: 10.1007/s00464-020-07486-8

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  34 in total

1.  Segmental duodenectomy for gastrointestinal stromal tumor of the duodenum.

Authors:  Nicolas Christian Buchs; Pascal Bucher; Pascal Gervaz; Sandrine Ostermann; François Pugin; Philippe Morel
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

3.  The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.

Authors:  Thomas Tran; Jessica A Davila; Hashem B El-Serag
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

4.  Multi-center study regarding the risk factors for bleeding in gastrointestinal stromal tumor.

Authors:  Kyung Sik Park; Kyu Chan Huh; Ilseon Hwang; Jung Hyeok Kwon; Joong Goo Kwon; Gwang Ha Kim; Jeong Eun Shin; Eun Soo Kim; Kwang Bum Cho
Journal:  Hepatogastroenterology       Date:  2013 Mar-Apr

Review 5.  Management of malignant gastrointestinal stromal tumours.

Authors:  Heikki Joensuu; Christopher Fletcher; Sasa Dimitrijevic; Sandra Silberman; Peter Roberts; George Demetri
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

Review 6.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

7.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

Review 9.  The epidemiology and pathogenesis of neoplasia in the small intestine.

Authors:  David Schottenfeld; Jennifer L Beebe-Dimmer; Fawn D Vigneau
Journal:  Ann Epidemiol       Date:  2009-01       Impact factor: 3.797

10.  Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients.

Authors:  Salvatore Caterino; Laura Lorenzon; Niccolò Petrucciani; Elsa Iannicelli; Emanuela Pilozzi; Adriana Romiti; Marco Cavallini; Vincenzo Ziparo
Journal:  World J Surg Oncol       Date:  2011-02-01       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.